Riken Corporation

Hiroshi Watarai

Masaru Taniguchi

Kenji Mori

Takuya Tashiro

Masao Shiozaki

Ryusuke Nakagawa

Shin-ichiro Fujii

Haruhiko Koseki

Ken-ichi Fuhshuku

Tomokuni Shigeura

Ken-Ichi Fuhshuku

The present invention provides an agent for an immunocyte therapy, comprising an NKT cell obtained by differentiating in vitro a cell having the &#x3b1;-chain region of the T cell receptor gene rearranged to uniform V&#x3b1;-J&#x3b1; in an NKT cell receptor-specific way, wherein an administration subject is an allogenic individual having MHC gene loci including at least one locus having a genotype different from that of the NKT cell. In addition, the present invention provides a bank of a human cell or an NKT cell derived from said cell, wherein the &#x3b1;-chain region of a T cell receptor (TCR) gene has been rearranged to uniform V&#x3b1;-J&#x3b1;. The agent and cell bank of the present invention are useful for the prophylaxis and/or treatment of cancer, infection, an allergic disease or an autoimmune disease.

Immunotherapy using allo-NKT cells, cells for immunotherapy in which alpha chain of t-cell receptor (TCR) gene has been rearranged to uniform V&#x3b1;-J&#x3b1;, and banking of NKT cells derived from said cells

The invention provides a compound effective as an antitumor active agent or vaccine adjuvant and an intermediate useful for the synthesis of the compound, as well as production methods thereof, and a medicament containing the novel compound. The compound is a carbamate glycolipid represented by the formula (I) wherein each symbol is as defined herein. The invention also provides a dendritic cell pulsed with the glycolipid.

Carbamate glycolipid and use thereof

The invention provides a compound represented by the formula (I) wherein Ris a hydrogen atom or a hydroxyl group; two Rare the same or different and each is a hydrogen atom or a hydroxyl group; Ris a hydrocarbon group having 8-14 carbon atoms, which optionally has substituent(s); and Ris a hydrocarbon group having 18-24 carbon atoms, which optionally has substituent(s), or a salt thereof. The invention also provides a method of treating an autoimmune disease or suppressing immunity by administering the aforementioned compound or a salt thereof to a patient in need thereof.

Hydroxylated KRN7000 analogue and use thereof

Provided are an iPS cell derived from a somatic cell such as an NKT cell, having the &#x3b1;-chain region of the T cell antigen receptor gene rearranged to uniform V&#x3b1;-J&#x3b1; in an NKT cell receptor-specific way, NKT cells differentiated from the iPS cell, a method of creating the same, and an immune cell therapy agent prepared using cells differentiated from the iPS cell. Also provided are an iPS cell having TCR&#x3b1; rearranged to NKT-TCR (NKT-iPS cell), obtained by contacting a somatic cell, such as an NKT cell, having the &#x3b1;-chain region of the T cell antigen receptor gene rearranged to uniform V&#x3b1;-J&#x3b1; in an NKT cell receptor-specific way, with nuclear reprogramming factors, isolated NKT cells obtained by differentiating the iPS cell ex vivo (iPS-NKT cell), a method of generating CD4/CD8-double positive NKT cells (DP-NKT cells) and mature NKT cells from NKT-iPS cells by altering the combination of feeder cells and/or cytokines, a method of expanding the iPS-NKT cells, and an NKT cell cytotherapy agent comprising NKT cells activated with &#x3b1;-galactosyl ceramide (&#x3b1;-GalCer), or iPS-NKT cells, and &#x3b1;-GalCer in combination.

Generating a mature NKT cell from a reprogrammed somatic cell with a T-cell antigen receptor &#x3b1;-chain region rearranged to uniform Va-Ja in a NKT-cell specific way

A compound represented by the following formula (1): wherein Ris an aldopyranose residue wherein the 6-hydroxyl group is optionally alkylated, Ris a Chydrocarbon group optionally having substituent(s), Ris a hydrogen atom or a Chydrocarbon group optionally having substituent(s), Ris a Chydrocarbon group optionally having substituent(s), X is an oxygen atom or &#x2014;CH&#x2014;, and Y is &#x2014;CH&#x2014;, &#x2014;CH(OH)&#x2014; or &#x2014;CH&#x2550;CH&#x2014;, or a salt thereof is useful for the prophylaxis or treatment of cancer or infection, since it can preferentially induce production of IFN-&#x3b3; of NKT cells.

Synthetic glycolipid and use thereof

The invention provides esterified &#x3b1;-galactosylceramides effective for cancer treatment and the like, and a medicament containing same. In particular, the invention relates to a compound represented by the formula (I): wherein Ris a hydrocarbon group having a carbon number of 1 to 30, Ris a hydrocarbon group having a carbon number of 1 to 20, Ris a hydrogen atom or hydrocarbon group having a carbon number of 1 to 5, Rand Rare the same or different and each is a hydrogen atom or a hydrocarbon group having a carbon number of 1 to 5, or Rand Rin combination form a divalent hydrocarbon group having a carbon number of 1 to 5, and optionally form a ring structure together with the adjacent ethylenedioxy, or a salt thereof.

Esterified &#x3b1;-galactosylceramide

The invention provides a glycolipid effective for cancer treatment and the like and a synthetic intermediate therefor, as well as a medicament containing the glycolipid and the like. The glycolipid is represented by the formula (1) or a salt thereof 

Glycolipid and use thereof

The invention provides a method of screening a therapeutic agent for allergic airway inflammation and/or airway hypersensitivity, comprising using an IL-17RB positive NKT cell, as well as a therapeutic agent for allergic airway inflammation and/or airway hypersensitivity, containing a substance capable of inhibiting or eliminating the Th2 cell-like function of an IL-17RB positive NKT cell as an active ingredient.

Methods for treating allergic airway inflammation, airway hypersensitivity, and eosinophilia

The invention provides a pseudoglycolipid effective for cancer treatment and the like and a novel synthesis intermediate therefor, as well as a medicament containing the pseudoglycolipid and the like. The inventive compound is represented by the formula (1), or a salt thereof, wherein each symbol is as defined in the specification.

Growing community of inventors

Kanagawa, Japan

Hiroshi Watarai